Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels.
作者信息
Heaney Jennifer L J, Richter Alex, Bowcock Stella, Pratt Guy, Child J Anthony, Jackson Graham, Morgan Gareth, Turesson Ingemar, Drayson Mark T
机构信息
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
King's College Hospital NHS Trust, London, UK.
出版信息
Haematologica. 2020 Apr;105(4):e169-e171. doi: 10.3324/haematol.2019.224360. Epub 2019 Aug 8.
Abstract
摘要
相似文献
1
Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels.
Haematologica. 2020 Apr;105(4):e169-e171. doi: 10.3324/haematol.2019.224360. Epub 2019 Aug 8.
2
3
Benefits of new immunoglobulin-derived biomarkers for the diagnosis and follow-up of patients with dysglobulinemia.
Ann Biol Clin (Paris). 2016 Oct 1;74(5):597-605. doi: 10.1684/abc.2016.1180.
4
Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.
Br J Haematol. 2016 Jul;174(1):81-7. doi: 10.1111/bjh.14026. Epub 2016 Mar 27.
5
Free light chain testing in follow-up of multiple myeloma.
Clin Chem Lab Med. 2006;44(8):1044-6. doi: 10.1515/CCLM.2006.188.
6
[A simple procedure for the reliable determination of free L-chains in the serum].
Folia Haematol Int Mag Klin Morphol Blutforsch. 1981;108(4):553-8.
7
Investigating the utility of saliva immunoglobulins for the detection of myeloma and using myeloma proteins to clarify partition between oral and systemic immunity.
Eur J Haematol. 2022 Jun;108(6):493-502. doi: 10.1111/ejh.13758. Epub 2022 Feb 28.
8
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
Haematologica. 2017 Mar;102(3):e104-e107. doi: 10.3324/haematol.2016.154070. Epub 2016 Dec 1.
9
Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
Pathol Biol (Paris). 2015 Sep;63(4-5):215-21. doi: 10.1016/j.patbio.2015.06.001. Epub 2015 Aug 28.
10
Quantification by Ultrafiltration and Immunofixation Electrophoresis Testing for Monoclonal Serum Free Light Chains.
Lab Med. 2020 Nov 2;51(6):592-600. doi: 10.1093/labmed/lmaa012.
引用本文的文献
1
Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial.
Cancers (Basel). 2023 Jun 25;15(13):3337. doi: 10.3390/cancers15133337.
2
Monoclonal gammopathy of increasing significance: time to screen?
Haematologica. 2023 Jun 1;108(6):1476-1486. doi: 10.3324/haematol.2022.281802.
3
Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study.
Biomedicines. 2022 Jul 10;10(7):1657. doi: 10.3390/biomedicines10071657.
4
A Cohort Study of Free Light Chain Ratio in Combination with Serum Protein Electrophoresis as a First-Line Test in General Practice.
Cancers (Basel). 2022 Jun 14;14(12):2930. doi: 10.3390/cancers14122930.
5
Investigating the utility of saliva immunoglobulins for the detection of myeloma and using myeloma proteins to clarify partition between oral and systemic immunity.
Eur J Haematol. 2022 Jun;108(6):493-502. doi: 10.1111/ejh.13758. Epub 2022 Feb 28.
本文引用的文献
1
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2019 Jan;20(1):57-73. doi: 10.1016/S1470-2045(18)30687-9. Epub 2018 Dec 14.
2
Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016.
JAMA Oncol. 2018 Sep 1;4(9):1221-1227. doi: 10.1001/jamaoncol.2018.2128.
3
Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests.
Br J Haematol. 2017 Jul;178(2):220-230. doi: 10.1111/bjh.14753. Epub 2017 Jun 1.
4
Presenting Signs of Multiple Myeloma and the Effect of Diagnostic Delay on the Prognosis.
J Am Board Fam Med. 2016 Nov 12;29(6):702-709. doi: 10.3122/jabfm.2016.06.150393.
5
Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool.
Clin Chem Lab Med. 2017 Mar 1;55(3):424-434. doi: 10.1515/cclm-2016-0194.
6
Quantifying the risk of multiple myeloma from symptoms reported in primary care patients: a large case-control study using electronic records.
Br J Gen Pract. 2015 Feb;65(631):e106-13. doi: 10.3399/bjgp15X683545.
7
Serum free light chains in patients with HIV infection: their association with markers of disease severity and antiretroviral use.
J Clin Pathol. 2015 Feb;68(2):148-53. doi: 10.1136/jclinpath-2014-202733. Epub 2014 Dec 1.
8
Comparison of cancer diagnostic intervals before and after implementation of NICE guidelines: analysis of data from the UK General Practice Research Database.
Br J Cancer. 2014 Feb 4;110(3):584-92. doi: 10.1038/bjc.2013.791. Epub 2013 Dec 24.
9
Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden.
Blood. 2014 Jan 16;123(3):338-45. doi: 10.1182/blood-2013-05-505487. Epub 2013 Nov 12.
10
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
Lancet. 2010 Dec 11;376(9757):1989-99. doi: 10.1016/S0140-6736(10)62051-X. Epub 2010 Dec 3.
Zotero 插件